Literature DB >> 27690551

Treatment Controversies in Adult ADHD.

James J McGough1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 27690551     DOI： 10.1176/appi.ajp.2016.15091207

Source DB:  PubMed          Journal:  Am J Psychiatry        ISSN： 0002-953X            Impact factor:   18.112


× No keyword cloud information.
  5 in total

1.  Late-Onset ADHD Reconsidered With Comprehensive Repeated Assessments Between Ages 10 and 25.

Authors:  Margaret H Sibley; Luis A Rohde; James M Swanson; Lily T Hechtman; Brooke S G Molina; John T Mitchell; L Eugene Arnold; Arthur Caye; Traci M Kennedy; Arunima Roy; Annamarie Stehli
Journal:  Am J Psychiatry       Date:  2017-10-20       Impact factor: 18.112

2.  Efficacy and Safety of SHP465 Mixed Amphetamine Salts in the Treatment of Attention-Deficit/Hyperactivity Disorder in Adults: Results of a Randomized, Double-Blind, Placebo-Controlled, Forced-Dose Clinical Study.

Authors:  Richard H Weisler; Michael Greenbaum; Valerie Arnold; Ming Yu; Brian Yan; Margo Jaffee; Brigitte Robertson
Journal:  CNS Drugs       Date:  2017-08       Impact factor: 5.749

3.  Prevalence and comorbidity of attention deficit hyperactivity disorder in Spain: study protocol for extending a systematic review with updated meta-analysis of observational studies.

Authors:  Ferrán Catalá-López; Manuel Ridao; Amparo Núñez-Beltrán; Ricard Gènova-Maleras; Adolfo Alonso-Arroyo; Rafael Aleixandre-Benavent; Miguel A Catalá; Rafael Tabarés-Seisdedos
Journal:  Syst Rev       Date:  2019-02-11

4.  Low recognition of attention deficit hyperactivity disorder in adult patients admitted to the Epilepsy Monitoring Unit.

Authors:  Caitlynn Pham; Cayla Roy; Christine Tang; Atul Maheshwari
Journal:  Brain Behav       Date:  2022-07-27       Impact factor: 3.405

5.  Assessing Palatability of a New Amphetamine Extended-Release Tablet Formulation for the Treatment of ADHD.

Authors:  Antonio Pardo; Thomas R King; Eman Rafla; Judith C Kando
Journal:  Drug Des Devel Ther       Date:  2021-07-08       Impact factor: 4.162
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.